Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox

Antimicrob Agents Chemother. 2008 May;52(5):1837-9. doi: 10.1128/AAC.01454-07. Epub 2008 Mar 10.

Abstract

L-buthionine (S,R)-sulfoximine (BSO) at a dose of 220 mg/kg of body weight/day showed an anti-Trypanosoma cruzi effect in infected mice, increasing their survival rate and decreasing the parasitemias and parasite burden in the hearts. Treatment with BSO plus nifurtimox caused an increase in the survival rate in comparison to the rates with treatment with each drug alone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Animals
  • Buthionine Sulfoximine / pharmacology*
  • Buthionine Sulfoximine / therapeutic use
  • Chagas Disease / drug therapy*
  • Chagas Disease / mortality
  • Chagas Disease / parasitology
  • Disease Models, Animal
  • Drug Synergism
  • Drug Therapy, Combination
  • Mice
  • Mice, Inbred BALB C
  • Nifurtimox / pharmacology*
  • Nifurtimox / therapeutic use
  • Survival Rate
  • Trypanocidal Agents / pharmacology
  • Trypanosoma cruzi / drug effects*

Substances

  • Trypanocidal Agents
  • Buthionine Sulfoximine
  • Nifurtimox